Table 2.
Differences in prognosis between patients with early versus late disease progression in patients with different subtypes of MZL
| Study | N | Classification | Definition of POD24 | Treatment | POD24 rate | OS(POD24) | OS(non-POD24) | HR/P |
|---|---|---|---|---|---|---|---|---|
| Luminar48 | N = 321 | MZL | POD24; POD occurred within 24 months after diagnosis | Alk-Mono (n = 16) ;R-Mono(n = 30 );R-Alkylating(n = 83);R-CHOP(n = 48); BR (n = 112) ;R-Fludarabinen(= 3 ) ;Other(n = 21) | 18% |
53% (3years) |
88% (3years) |
HR = 19.5 p < 0.001 |
| Conconi49 | N = 401 | MALT | POD2;progression within 24 months from the start of first-line treatment |
Chemotherapy only(n = 131);Rituximab and chemotherapy(n = 132); R-Mono (n = 138) |
18% |
64% (10years) |
85% (10years) |
HR = 2.42 |
| Lu50 | N = 106 | SMZL | POD24: POD occurred within 24 from diagnosis |
CHOP/COP/FC(n = 20); R + CHOP /COP/FC(n = 54); splenectomy (n = 11); R only(n = 4); combination of the proposed approaches (n = 17) |
16.0% | - | - | HR = 20.116 |
| Epperla51 | N = 364 | MZL | POD24: POD occurred within 24 from systemic therapy initiation | R-Mono | 28% |
75% (5years) |
88% (5years) |
p = 0.007 |
| ICT |
69% (5years) |
94% (5years) |
p < 0.0001 |
MZL: Marginal zone lymphomas; POD = Progression of disease; HR = Hazard Rates; Alk = alkylating agent; B = Bendamustine ; R-Mono = rituximab monotherapy; CHOP = cyclophosphamide, doxorubicin, vincristine, and prednisone; ICT = immunochemotherapy; FC = fludarabine, cyclophosphamide